Taf + Emtricitabine + Rilpivirine Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: (TAF) – 25 mg + Emtricitabine – 200 mg + Rilpivirine – 25 mg
Reference Brands: Odefsey(US & EU)
Category:
Anti Viral
Odefsey is a once-daily HIV-1 treatment combining TAF, Emtricitabine, and Rilpivirine. FDA and EMA approved, it offers improved kidney and bone safety compared to TDF-based regimens and must be taken with food.
TAF + Emtricitabine + Rilpivirine is available in Tablet
and strengths such as (TAF) – 25 mg + Emtricitabine – 200 mg + Rilpivirine – 25 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, TAF + Emtricitabine + Rilpivirine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
TAF + Emtricitabine + Rilpivirine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Odefsey is a once-daily, fixed-dose combination tablet containing Tenofovir Alafenamide (TAF) 25 mg, Emtricitabine 200 mg, and Rilpivirine 25 mg, used for the treatment of HIV-1 infection in virologically suppressed patients or treatment-naïve individuals without resistance to its components. Approved by the FDA and EMA, Odefsey is a TAF-based alternative to older TDF regimens like Complera/Eviplera, offering improved renal and bone safety. It is indicated for adults and adolescents (≥12 years and ≥35 kg) and must be taken with a meal. Odefsey simplifies therapy by combining three potent agents into a single-tablet regimen.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing